Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claus Vogelmeier

Showing results (1-10 of 158) with videos related to

Pageof 16
Sort By:
The European Respiratory Journal|April 2, 2014
COPD assessment: I, II, III, IV and/or A, B, C, DClaus Vogelmeier, Jørgen Vestbo
Therapeutic Advances in Respiratory Disease|April 23, 2011
NVA237, a long-acting muscarinic antagonist, as an emerging therapy for chronic obstructive pulmonary diseaseClaus Vogelmeier, Donald Banerji
Expert Opinion on Emerging Drugs|March 7, 2009
Emerging drugs in chronic obstructive pulmonary diseaseCarola Seifart, Claus Vogelmeier
Expert Review of Respiratory Medicine|July 14, 2012
Future of chronic obstructive pulmonary disease managementAnthony D'Urzo, Claus Vogelmeier
Der Pneumologe|July 5, 2021
[Genetics of pulmonary diseases]Claus Vogelmeier, Bernd Schmeck
American Journal of Respiratory and Critical Care Medicine|June 5, 2007
Chronic obstructive pulmonary disease and premature agingClaus Vogelmeier, Robert Bals
Medizinische Klinik (Munich, Germany : 1983)|May 20, 2008
[Budesonide/formoterol maintenance and reliever therapy. A new treatment approach for adult patients with asthma]Stephanie Korn, Claus Vogelmeier, Roland Buhl
American Journal of Physiology. Lung Cellular and Molecular Physiology|September 23, 2020
COPD 2020: changes and challengesAlvar Agustí, Claus Vogelmeier, Rosa Faner
Respiratory Medicine|November 29, 2015
Achieving asthma control with ICS/LABA: A review of strategies for asthma management and preventionRené Aalbers, Claus Vogelmeier, Piotr Kuna
Respiratory Research|June 23, 2010
Outcome measures in chronic obstructive pulmonary disease (COPD): strengths and limitationsThomas Glaab, Claus Vogelmeier, Roland Buhl
Pageof 16

Showing results (1-10 of 158) with videos related to

Sort By:
Pageof 16
The European Respiratory Journal|April 2, 2014
COPD assessment: I, II, III, IV and/or A, B, C, DClaus Vogelmeier, Jørgen Vestbo
Therapeutic Advances in Respiratory Disease|April 23, 2011
NVA237, a long-acting muscarinic antagonist, as an emerging therapy for chronic obstructive pulmonary diseaseClaus Vogelmeier, Donald Banerji
Expert Opinion on Emerging Drugs|March 7, 2009
Emerging drugs in chronic obstructive pulmonary diseaseCarola Seifart, Claus Vogelmeier
Expert Review of Respiratory Medicine|July 14, 2012
Future of chronic obstructive pulmonary disease managementAnthony D'Urzo, Claus Vogelmeier
Der Pneumologe|July 5, 2021
[Genetics of pulmonary diseases]Claus Vogelmeier, Bernd Schmeck
American Journal of Respiratory and Critical Care Medicine|June 5, 2007
Chronic obstructive pulmonary disease and premature agingClaus Vogelmeier, Robert Bals
Medizinische Klinik (Munich, Germany : 1983)|May 20, 2008
[Budesonide/formoterol maintenance and reliever therapy. A new treatment approach for adult patients with asthma]Stephanie Korn, Claus Vogelmeier, Roland Buhl
American Journal of Physiology. Lung Cellular and Molecular Physiology|September 23, 2020
COPD 2020: changes and challengesAlvar Agustí, Claus Vogelmeier, Rosa Faner
Respiratory Medicine|November 29, 2015
Achieving asthma control with ICS/LABA: A review of strategies for asthma management and preventionRené Aalbers, Claus Vogelmeier, Piotr Kuna
Respiratory Research|June 23, 2010
Outcome measures in chronic obstructive pulmonary disease (COPD): strengths and limitationsThomas Glaab, Claus Vogelmeier, Roland Buhl
Pageof 16